Framework for Accountability of Anonymous Contributors in Biotech DAOs

1. Introduction

A Decentralized Autonomous Organization (DAO) is an organization that coordinates activities through blockchain-based smart contracts, governance tokens, decentralized voting, and online communities. In biotechnology, DAOs may finance genetic research, develop open-source laboratory technologies, support synthetic biology, fund drug discovery, or manage decentralized scientific data.

Anonymous contributors may participate as developers, researchers, token holders, funders, data analysts, or governance delegates without publicly disclosing their legal identities. While anonymity can encourage scientific collaboration and protect whistleblowers, it creates accountability challenges when contributions cause biological harm, violate research regulations, misuse genetic information, or facilitate unauthorized experiments.

The central legal question is: How can a biotech DAO impose responsibility on anonymous contributors without eliminating legitimate privacy and decentralized participation?

The answer requires a framework combining identity verification where legally necessary, traceable decision-making, smart-contract governance, research oversight, liability allocation, and judicial remedies. Importantly, anonymity does not automatically confer immunity from civil, criminal, regulatory, or contractual liability.

2. Meaning and legal challenges

Accountability in biotech DAOs refers to mechanisms that identify responsible actors, establish their participation in decisions, investigate misconduct, and impose appropriate remedies.

Three difficulties are particularly significant:

Pseudonymous participation: Blockchain addresses do not necessarily reveal the real-world identity of their controllers.

Distributed decision-making: Responsibility may be divided among token holders, developers, research institutions, laboratories, and funding entities.

Scientific uncertainty: Biological harms may emerge gradually, making it difficult to connect a particular contribution with the eventual damage.

For example, a DAO might collectively approve funding for a genetically modified microorganism. If the organism escapes a contained laboratory, investigators must determine who authorized the project, who conducted the experiments, whether safety requirements were followed, and whether any participant knowingly facilitated the breach.

A token vote alone cannot answer these questions. Accountability requires evidence of actual conduct, authority, knowledge, causation, and applicable legal duties.

3. Essential components of the accountability framework

A. Legal recognition and organizational responsibility

A biotech DAO should adopt a legally recognized structure, such as a company, nonprofit entity, foundation, or jurisdictionally available DAO entity. The structure should identify who holds assets, enters research agreements, employs scientists, and bears regulatory responsibilities.

Legal recognition does not eliminate individual liability for fraud, negligence, unlawful research, or intentional misconduct. Nor does decentralization automatically make every token holder personally liable.

B. Identity verification and conditional anonymity

The framework should distinguish between public anonymity and legally verifiable identity.

Public-facing anonymity: Contributors may use pseudonyms in discussions and scientific collaborations.

Confidential verification: Individuals exercising high-risk privileges may undergo identity verification through an independent compliance provider.

Regulatory disclosure: Identities should be disclosed to competent authorities when legally required.

Risk-based access: Anonymous contributors may participate in ordinary discussions, but sensitive research approvals, controlled-material transactions, and legally restricted activities may require verified authorization.

This approach protects legitimate privacy while ensuring that individuals responsible for regulated activities can be identified when necessary.

C. Traceability of governance decisions

Every significant research proposal should generate an auditable record containing:

The proposal and its scientific justification.

Voting addresses and recorded voting outcomes.

Conflicts of interest and relevant disclosures.

The identity or authorized role of the project supervisor.

Safety assessments and regulatory approvals.

The allocation of funds and responsibility for monitoring.

Subsequent amendments, incidents, and corrective measures.

Blockchain records can establish that a particular address voted or transferred funds. However, they do not necessarily prove who controlled the address, whether the person understood the consequences, or whether the vote caused the eventual harm.

D. Allocation of liability

A biotech DAO should distinguish among different forms of participation.

Mere possession of governance tokens or anonymous participation should not automatically establish individual liability. The relevant law, the person's conduct, and the evidence must determine responsibility.

4. Important case laws

The following cases concern DAO governance, anonymity, and accountability. They are not biotechnology-specific precedents, but their principles are relevant to biotech DAOs.

1. CFTC v. Ooki DAO (2023)

The United States District Court for the Northern District of California held that Ooki DAO could be treated as a suable unincorporated association under the applicable law. In June 2023, the court entered a default judgment imposing a civil monetary penalty of $643,542 and ordering the cessation of the unlawful activities at issue. The litigation concerned violations of US commodity-trading law.

CFTC

+1

Legal principle: A DAO cannot necessarily avoid legal proceedings merely because it operates through decentralized governance and blockchain-based voting.

Application to biotech: A DAO funding unlawful biological research could face enforcement even where its organizational structure is decentralized. Contributors who exercised control or performed legally relevant acts may also face individual proceedings where the applicable law supports them.

The judgment against the DAO should not be interpreted as establishing automatic liability for every anonymous participant.

2. Sarcuni v. bZx DAO (2023)

In this US federal case, plaintiffs alleged that security failures associated with the bZx protocol led to substantial cryptocurrency losses. The court allowed claims based on a potential general-partnership theory to proceed at the pleading stage. It did not thereby establish that every token holder was ultimately liable.

Goodwin

+1

Legal principle: Governance participation and the legal structure of a DAO can create liability risks that depend on the facts and applicable partnership law.

Application to biotech: Contributors who actively direct a research enterprise, share profits, and participate in its management may face greater exposure than passive participants. Whether partnership status exists must be determined under the relevant jurisdiction's law.

3. SEC v. W.J. Howey Co. (1946)

The US Supreme Court developed the Howey test for determining whether an arrangement constitutes an investment contract under US securities law. The analysis considers an investment of money in a common enterprise, an expectation of profits, and reliance on the entrepreneurial or managerial efforts of others.

Application to biotech: A biotech DAO issuing tokens to finance drug discovery or genetic-engineering projects may need to assess whether its token arrangements constitute securities. The classification depends on the economic substance and circumstances, not simply on whether the project calls itself decentralized.

This case does not directly establish liability for anonymous contributors, but it illustrates why financial and governance arrangements require legal scrutiny.

4. The DAO Report, SEC (2017)

The US Securities and Exchange Commission concluded that tokens issued by The DAO constituted securities under the circumstances examined and that federal securities laws applied. The report emphasized that using distributed-ledger technology does not remove the applicability of existing securities laws.

Application to biotech: Anonymous token holders and funders cannot assume that blockchain-based fundraising exempts a biotechnology project from financial regulation. The report supports regulatory accountability, although it is not a judicial judgment on contributor liability.

5. Indian legal framework

India does not have a comprehensive, DAO-specific statute establishing a universal liability regime for anonymous contributors. The applicable rules therefore depend on the DAO's legal structure, activities, location, and the nature of the alleged misconduct.

Relevant legal provisions include:

Companies Act, 2013: Section 3 provides for the formation of companies for lawful purposes. A properly constituted entity can hold assets, enter contracts, and establish governance responsibilities.

3

Environment (Protection) Act, 1986, and Rules, 1989: These establish the framework for regulating hazardous microorganisms and genetically engineered organisms. The Genetic Engineering Appraisal Committee (GEAC) appraises specified high-risk activities and proposals involving environmental release.

GeAC India

+1

Information Technology Act, 2000: Electronic records and communications may be relevant to proving governance decisions, digital transactions, and online misconduct, subject to applicable evidentiary requirements.

India Code

A DAO cannot replace statutory biosafety approval with a token-holder vote. Where applicable, institutional biosafety committees and competent regulatory authorities retain their statutory functions.

6. Recommended accountability model

A practical framework should combine six safeguards:

1. Legal entity and accountable officers

Establish a suitable legal entity and designate responsible officers for research safety, finances, compliance, and incident reporting.

2. Risk-based identity verification

Permit pseudonyms for ordinary participation while requiring verified credentials for legally restricted activities and high-risk approvals.

3. Independent biosafety review

Require qualified scientific assessment, appropriate permits, documented risk evaluations, and independent audits before regulated projects proceed.

4. Traceable governance

Preserve proposals, voting records, funding decisions, approvals, and relevant off-chain evidence with appropriate access controls.

5. Individualized liability assessment

Investigate each person's actual conduct, authority, knowledge, and causal contribution rather than attributing automatic guilt to all token holders.

6. Remedies and incident response

Establish reporting channels, emergency suspension procedures, compensation arrangements, cooperation with authorities, and protection for whistleblowers.

7. Privacy and due process

Accountability must not become indiscriminate surveillance. Identity information should be collected only when necessary, protected against unauthorized disclosure, and accessible to authorized investigators under appropriate safeguards.

The European Data Protection Board's 2025 blockchain guidelines emphasize the importance of assigning responsibilities, assessing privacy risks, and designing systems that can respect data-subject rights. These principles are particularly relevant where biotech DAOs process genetic or medical data.

European Data Protection Board

+1

Anonymous contributors must also receive fair procedures, including notice of allegations, an opportunity to respond, impartial investigation, and proportionate sanctions. Smart contracts should not automatically impose irreversible penalties based solely on unverified accusations.

8. Conclusion

The accountability of anonymous contributors in biotech DAOs requires a balance between decentralized innovation, privacy, biosafety, and legal responsibility. The cases concerning Ooki DAO and bZx demonstrate that decentralized governance does not necessarily prevent courts from examining the responsibilities of an organization and its participants.

The strongest framework combines legal recognition, conditional anonymity, auditable governance, independent biosafety oversight, and evidence-based allocation of liability. In India, these safeguards must operate alongside applicable company, environmental, biotechnology, and digital-evidence laws.

The governing principle is that anonymity may protect a contributor's public identity, but it must not become a mechanism for evading lawful accountability.